International Journal on Science and Technology

E-ISSN: 2229-7677   •   Impact Factor: 9.88

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 17 Issue 3 July-September 2026 Submit your research before last 3 days of September to publish your research paper in the issue of July-September.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 17 Issue 3
July-September 2026

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Comparison of Ketoralc Tromethamine and Cyclophosphamide Against the Antigenic Peptide of Esr1 (Breast Cancer) using Insilico Techniques

Author(s) Ms. Anu Augustine, Prof. Dr. Geethalakshmi S, Mr. Syamkumar T S
Country India
Abstract Background: To investigate the possible efficacy of NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) against the Estrogen Receptor 1 (ESR1) Antigenic peptide (Model Archive (https://modelarchive.org/doi/10.5452/ma-9z6ga) using insilico procedures. Objectives: The primary goal of our current work is to dock the modelled ESR1 peptide (Breast cancr) with an anti-inflammatory drug. Drug docking studies were performed in order to predict the efficacy of ketoralc tromethamine against ESR1 peptide. Materials and methods: The UniProt database provided the genomic sequence of ESR1-Peptide, which was then docked using the CBDOCK server with ketoralc tromethamine, an anti-inflammatory medication currently in use, and Cyclophosphamide, a control agent. Results and discussion: The current study demonstrates that the reference medication, Cyclophosphamide, and ketoralc tromethamine interact with ESR1-peptide in an efficient manner. The docking score was used to assess the compound's efficacy against the protein that causes breast cancer. Compared to the control medication Cyclophosphamide, ketoralc tromethamine exhibits a higher binding affinity. Therefore, when used in conjunction with novel medications to target the anti-cancer activity protein ESR1 in human breast cancer, ketoralc tromethamine may be considered a viable choice. Conclusion: This study's conclusion is that anti-cancer medications successfully block ESR1. The results of this study have a substantial influence on the field of current cancer informatics research.
Keywords Keywords: Estrogen Receptor 1 (ESR1), ketoralc tromethamine, Cyclophosphamide (reference medication), Model Archive, (CBDOCK, and Discovery Studio.
Published In Volume 17, Issue 3, July-September 2026
Published On 2026-08-03
View / Download PDF File

Share this


CrossRef

Crossref DOI prefix of IJSAT is 10.71097/IJSAT

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 17 Isu 2Cover Page Vol 17 Isu 1Cover Page Vol 16 Isu 4

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJSAT
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics 		Join as a Reviewer
Editors & Reviewers
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us Message on WhatsApp +91-9687-182-185 editor@ijsat.org